cAMP-mediated signal transduction and sarcoplasmic reticulum function in heart failure

Annals of the New York Academy of Sciences

Volumn 853, Issue , 1998, Pages 231-239

  Movsesian, Matthew A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP PHOSPHODIESTERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; PHOSPHOLAMBAN; PHOSPHOTRANSFERASE;

CALCIUM TRANSPORT; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN PHOSPHORYLATION; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

EID: 0031792161     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb08271.x     Document Type: Conference Paper

References (60)

1. SCULPTOREANU, A., E. ROTMAN, M. TAKAHASHI, T. SCHEUER & W. A. CATTERALL. 1993. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 90: 10135-10139.
2. DE JONGH, K. S., B. J. MURPHY, A. A. COLVIN, J. W. HELL, M. TAKAHASHI & W. A. CATTERALL. 1996. Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3′,5′-cyclic monophosphate-dependent protein kinase. Biochemistry 35: 10392-10402.
3. WITCHER, D. R., R. J. KOVACS, H. SCHULMAN, D. C. CEFALI & L. R. JONES. 1991. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J. Biol. Chem. 266: 11144-11152.
4. HAIN, J., H. ONOUE, M. MAYRLEITNER, S. FLEISCHER & H. SCHINDLER. 1995. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J. Biol. Chem. 270: 2074-2081.
5. SOLARO, R. J., S. P. ROBERTSON, J. D. JOHNSON, M. J. HOLROYDE & J. D. POTTER. 1981.
6. Troponin-I phosphorylation: A unique regulator of the amount of calcium required to activate cardiac myofibrils. Cold Spring Harbor Conf. Cell Proliferation 8: 901-911.
7. 2+ transport as studied by reconstitution of cardiac sarcoplasmic reticulum. J. Biol. Chem. 261: 1794-1800.
8. 2+ pump of the sarcoplasmic reticulum. Nature 342: 90-92.
9. 2+ pump ATPase. J. Biol. Chem. 267: 1674-1679.
10. LUO, W., I. L. GRUPP, J. HARRER, S. PONNIAH, G. GRUPP, J. J. DUFY, T. DOETSCHMAN & E. G. KRANIAS. 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ. Res. 75: 401-109.
11. FELDMAN, M. D., L. COPELAS, J. K. GWATHMEY, P. PHILLIPS, S. E. WARREN, F. J. SCHOEN & W. GROSSMAN. 1987. Deficient production of cyclic AMP: Pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331-339.
12. BENOVIC, J. L., M. BOUVIER, M. G. CARON & R. J. LEFKOWITZ. 1988. Regulation of adenylyl cyclase-coupled β-adrenergic receptors. Annu. Rev. Cell Biol. 4: 405-428.
13. GOODMAN, A. G. 1995. Nobel Lecture. G proteins and regulation of adenylyl cyclase. Biosci. Rep. 15: 65-97.
14. BRISTOW, M. R., R. GINSBURG, W. MINOBE, R. S. CUBICCIOTTI, W. S. SAGEMAN, K. LURIE, M. E. BILLINGHAM, D. C. HARRISON & E. B. STINSON. 1982. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N. Engl. J. Med. 307: 205-211.
15. 1-receptor down-regulation in heart failure. Circ. Res. 59: 297-309.
16. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol. Pharmacol. 35: 295-303.
17. FELDMAN, A. M., A. E. CATES, W. B. VEAZEY, R. E. HERSHBERGER, M. R. BRISTOW, K. L. BAUGHMAN, W. A. BAUMGARTNER & C. VAN DOP. 1988. Increase in the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J. Clin. Invest. 82: 189-197.
18. iα in human heart with dilated but not ischemic cardiomyopathy. Circulation 82: 1249-1265.
19. 1-adrenergic receptors in the failing human heart. Circulation 87: 454-463.
20. LOHSE, M. J., J. L. BENOVIC, A. J. CODIN, M. G. CARON & R. J. LEFKOWITZ. 1990. β-arrestin: A protein that regulates β-adrenergic receptor function. Science 248: 1547-1550.
21. LEFKOWITZ, R. J., J. INGLESE, W. J. KOCH, J. PITCHER, H. ATTRAMADAL & M. G. CARON. 1992. G-protein-coupled receptors: Regulatory role of receptor kinases and arrestin proteins. Cold Spring Harbor Symp. Quant. Biol. 57: 127-133.
22. FERGUSON, S. S., W. E. DOWNEY III, A. M. COLAPIETRO, L. S. BARAK, L. MENARD & M. G. CARON. 1996. Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271: 363-366.
23. 2-adrenergic receptors permit receptor resensitization. Mol. Pharmacol. 47: 666-676.
24. YU, S. S., R. J. OLEFKOWITZ & W. P. HAUSDORFF. 1993. β-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J. Biol. Chem. 268: 337-341.
25. LIMAS, C. J., M. T. OLIVAR, I. F. GOLDENBERG, T. B. LEVINE, D. G. BENDITT & A. SIMON.
26. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc. Res. 21: 601-605.
27. 2+-ATPase in failing and nonfailing human myocardium. Circ. Res. 75: 434-442.
28. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92: 3220-3228.
29. 2+ ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J. Mol. Med. 74: 321-332.
30. 2+ exchanger in end-stage human heart failure. Circ. Res. 75: 443-453.
31. MEYER, M., W. SCHILLINGER, B. PIESKE, C. HOLUBARSCH, C. HEILMANN, H. POSIVAL, G. KUWAJIMA, K. MIKOSHIBA, H. JUST & G. HASENFUSS. 1995. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92: 778-784.
32. MOVSESIAN, M. A., M. B. BRISTOW & J. KRALL. 1989. Calcium uptake by sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ. Res. 65: 1141-1144.
33. 2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J. Clin. Invest. 85: 1698-1702.
34. MOVSESIAN, M. A., C. J. SMITH, J. KRALL, M. R. BRISTOW & V. C. MANGANIELLO. 1991. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J. Clin. Invest. 88: 15-19.
35. 2+-transporting ATPase, phospholamban and calsequestrin levels in nonfailing and failing human myocardium. Circulation 90: 653-657.
36. 2+ accumulation in nonfailing and failing human myocardium. Circulation 92: 2504-2510.
37. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc. Res. 31: 625-632.
38. 2+-ATPase activity of SERCA II in human myocardium. (Abstr.) Circulation 9-1: 1-673.
39. ICHIKAWA, A., Y. SUGIMOTO & M. NEGISHI. 1996. Molecular aspects of the structures and functions of the prostaglandin E receptors. J. Lipid Mediat. Cell Signal. 14: 83-87.
40. NEGISHI, M., A. IRIE, Y. SUGIMOTO, T. NAMBA & A. ICHIKAWA. 1995. Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J. Biol. Chem. 270: 16122-16127.
41. 1. J. Biol. Chem. 255: 5113-5119.
42. BUXTON, I. L. & L. L. BRUNTON. 1983. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J. Biol. Chem. 258: 10233-10239.
43. 2+ dynamics, contractility, or phospholamban phosphorylation. J. Biol. Chem. 269: 19151-19156.
44. 2-adrenoceptor agonists in guinea pig hearts. J. Cardiovasc. Pharmacol. 26: 893-898.
45. 2+ transients. Circulation 69: 1369-1379.
46. 2+ current in single rat ventricular cells. Circ. Res. 73: 286-300.
47. CORBIN, J. D., P. H. SUGDEN, T. M. LINCOLN & S. L. KEELY. 1977. Compartmentalization of adenosine 3′:5′-monophosphate and adenosine 3′:5′-monophosphate-dependent protein kinase in heart tissue. J. Biol. Chem. 252: 3854-3861.
48. TAYLOR, S. S., J. A. BUECHLER & W. YONEMOTO. 1990. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu. Rev. Biochem. 59: 971-1005.
49. SCOTT, J. D. 1991. Cyclic nucleotide-dependent protein kinases. Pharmacol. Ther. 50: 123-145.
50. LEISER, M., C. S. RUBIN & J. ERLICHMAN. 1986. Differential binding of the regulatory subunits (RII) of cAMP-dependent protein kinase II from bovine brain and muscle to RII-binding proteins. J. Biol. Chem. 261: 1904-1908.
51. COGHLAN, V. M., S. E. BERGESON, L. LANGEBERG, G. NILAVER & J. D. SCOTT. 1993. A-Kinase anchoring proteins: A key to selective activation of cAMP-responsive events? Mol. Cell. Biochem. 127/128: 309-319.
52. ROBINSON, M. L., M. A. WALLERT, C. A. REINITZ & J. B. SHABB. 1996. Association of the type I regulatory subunit of cAMP-dependent protein kinase with cardiac myocyte sarcolemma. Arch. Biochem. Biophys. 330: 181-187.
53. BÖHM, M., B. REIGER, R. H. G. SCHWINGER & E. ERDMANN. 1994. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in nonfailing and failing myocardium. Cardiovasc. Res. 28: 1713-1719.
54. m cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem. Biophys. Res. Commun. 190: 516-521.
55. MOVSESIAN, M. A., C. J. SMITH, J. KRALL, M. R. BRISTOW & V. C. MANGANIELLO. 1991. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J. Clin. Invest. 88: 15-19.
56. MOVSESIAN, M. A., J. STAHELI & J. KRALL. 1995. Compartmentation of cAMP-dependent protein kinase in nonfailing and failing human myocardium. (Abstr.) J. Invest. Med. 43: 357A.
57. MASSIE, B., M. BOURASSA, R. DIBIANCO, M. HESS, M. KONSTAM, M. LIKOFF & M. PACKER. 1985. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 71: 963-971.
58. DIBIANCO, R., R. SHABETAI, W. KOSTUK, J. MORAN, R. C. SCHLANT & R. WRIGHT. 1989. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N. Engl. J. Med. 320: 677-683.
59. URETSKY, B. F., M. JESSUP, M. A. KONSTAM, C. V. DEC, G. W. LEIER, J. BENOTTI, S. MURALLI, H. C. HERRMANN & J. A. SANDBERG. 1990. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 82: 774-780.
60. NONY, P., J-P. BOISSEL, M. LIÈVRE, A. LEIZOROVICZ, M. C. HAUGH, S. FAREH, B. DE BREYNE. 1994. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. Eur. J. Clin. Pharmacol. 46: 191-196.